Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.40 and traded as low as $0.16. Bellicum Pharmaceuticals shares last traded at $0.19, with a volume of 61,587 shares.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on Bellicum Pharmaceuticals in a research report on Thursday. They set a “sell” rating for the company.
Bellicum Pharmaceuticals Stock Down 16.9 %
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Bellicum Pharmaceuticals stock. Boxer Capital LLC acquired a new position in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 450,000 shares of the biopharmaceutical company’s stock, valued at approximately $167,000. Boxer Capital LLC owned approximately 4.74% of Bellicum Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 4.93% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.
- Five stocks we like better than Bellicum Pharmaceuticals
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 large caps with red hot RSIs with upside
- How to Read Stock Charts for Beginners
- Johnson Controls International: Nothing but upside for investors
- Stock Market Sectors: What Are They and How Many Are There?
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.